Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients

Mondeshki et al., Cureus, doi:10.7759/cureus.58164
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
Case series of 3 morbidly obese COVID-19 patients, 2 outpatients and 1 hospitalized, showing rapid recovery with a therapeutic regimen including high-dose colchicine (5 mg loading dose followed by 1-3 mg daily maintenance dose). Authors hypothesize that the high colchicine doses are necessary to achieve sufficient intracellular concentrations to inhibit the NLRP3 inflammasome and cytokine storm in COVID-19.
Mondeshki et al., 13 Apr 2024, peer-reviewed, 2 authors. Contact: vmitev@mu-sofia.bg.
This PaperColchicineAll
High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients
Tsanko Mondeshki, Vanyo Mitev
Cureus, doi:10.7759/cureus.58164
Colchicine has long been known to possess anti-inflammatory effects by inhibiting microtubules, activation and migration of neutrophils, and most importantly, the inflammasome complex found in neutrophils and monocytes. Due to these properties, a number of clinical trials have tested the therapeutic effect of colchicine in COVID-19 patients. One common feature of these studies, however, is the low therapeutic dose used, which may explain the conflicting and disappointing results. Colchicine has the unique property of accumulating in leukocytes, which are primarily responsible for the hyperactivation of the NLRP3 inflammasome and the cytokine storm. The low-dose colchicine used to treat COVID-19 is not sufficient to reach the necessary intracellular concentration for NLRP3 inflammasome inhibition. We have reported our experience with high-dose colchicine, within the approved therapeutic range, in both ambulatory and hospitalized patients, and have shown dramatic cure rates. Here, we present our observation of an excellent therapeutic effect of high-dose colchicine in morbidly obese COVID-19 patients who are at the highest morbidity and mortality risk.
Additional Information Author Contributions All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work. Concept and design: Vanyo Mitev
References
Ahmed-Khan, Matar, Coombes, Moin, Joseph et al., Remdesivir-associated acute liver failure in a COVID-19 patient: a case report and literature review, Cureus, doi:10.7759/cureus.34221
Deng, Li, Zhang, Zhao, Wang, Targeting inflammasome activation in viral infection: a therapeutic solution?, Viruses, doi:10.3390/v15071451
Ellulu, Patimah, Khaza'ai, Rahmat, Abed, Obesity and inflammation: the linking mechanism and the complications, Arch Med Sci, doi:10.5114/aoms.2016.58928
Freeman, Swartz, Targeting the NLRP3 inflammasome in severe COVID-19, Front Immunol, doi:10.3389/fimmu.2020.01518
Hendren, De Lemos, Ayers, Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry, Circulation, doi:10.1161/CIRCULATIONAHA.120.051936
Jin, Yang, Chen, Zhang, Duan, Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches, Signal Transduct Target Ther, doi:10.1038/s41392-020-00454-7
Kadiyska, Tourtourikov, Dabchev, Role of endothelial dysfunction in the severity of COVID-19 infection (review), Mol Med Rep, doi:10.3892/mmr.2022.12867
Kalligeros, Shehadeh, Mylona, Benitez, Beckwith et al., Association of obesity with disease severity among patients with coronavirus disease 2019, Obesity, doi:10.1002/oby.22859
Lilov, Palaveev, Mitev, High doses of colchicine act as "silver bullets" against severe COVID-19, Cureus, doi:10.7759/cureus.54441
Mitev, Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended Paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib, Pharmacia, doi:10.3897/pharmacia.70.e112550
Mitev, What is the lowest lethal dose of colchicine?, Biotechnol Biotechnol Equip, doi:10.1080/13102818.2023.2288240
Mondeshki, Bilyukov, Mitev, Effect of an accidental colchicine overdose in a COVID-19 inpatient with bilateral pneumonia and pericardial effusion, Cureus, doi:10.7759/cureus.35909
Mondeshki, Bilyukov, Tomov, Mihaylov, Mitev, Complete, rapid resolution of severe bilateral pneumonia and acute respiratory distress syndrome in a COVID-19 patient: role for a unique therapeutic combination of inhalations with bromhexine, higher doses of colchicine, and hymecromone, Cureus, doi:10.7759/cureus.30269
Petrakis, Margină, Tsarouhas, Obesity -a risk factor for increased COVID-19 prevalence, severity and lethality (review), Mol Med Rep, doi:10.3892/mmr.2020.11127
Singh, Rathore, Khan, Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression, Front Endocrinol, doi:10.3389/fendo.2022.780872
Tiholov, Lilov, Georgieva, Palaveev, Tashkov et al., Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients, PREPRINT, doi:10.22541/au.171008530.09561084/v1
Van Schalkwyk, Buyer beware: molnupiravir may damage DNA, BMJ, doi:10.1136/bmj.n2663
Who, Obesity, Overweight, None
Zhou, Hill, Sarkar, β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells, J Infect Dis, doi:10.1093/infdis/jiab247
{ 'indexed': {'date-parts': [[2024, 4, 14]], 'date-time': '2024-04-14T00:24:35Z', 'timestamp': 1713054275112}, 'reference-count': 20, 'publisher': 'Springer Science and Business Media LLC', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 4, 13]]}, 'DOI': '10.7759/cureus.58164', 'type': 'journal-article', 'created': {'date-parts': [[2024, 4, 13]], 'date-time': '2024-04-13T07:51:35Z', 'timestamp': 1712994695000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients', 'prefix': '10.7759', 'author': [ {'given': 'Tsanko', 'family': 'Mondeshki', 'sequence': 'first', 'affiliation': []}, {'given': 'Vanyo', 'family': 'Mitev', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.3892/mmr.2020.11127', 'article-title': 'Obesity\xa0‑\xa0a risk factor for increased COVID‑19 prevalence, ' 'severity and lethality (review)', 'volume': '22', 'author': 'Petrakis D', 'year': '2020', 'unstructured': 'Petrakis D, Margină D, Tsarouhas K, et al.. Obesity\xa0‑\xa0a risk ' 'factor for increased COVID‑19 prevalence, severity and lethality ' '(review). Mol Med Rep. 2020, 22:9-19. 10.3892/mmr.2020.11127', 'journal-title': 'Mol Med Rep'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fendo.2022.780872', 'article-title': 'Association of obesity with COVID-19 severity and mortality: an updated ' 'systemic review, meta-analysis, and meta-regression', 'volume': '13', 'author': 'Singh R', 'year': '2022', 'unstructured': 'Singh R, Rathore SS, Khan H, et al.. Association of obesity with ' 'COVID-19 severity and mortality: an updated systemic review, ' 'meta-analysis, and meta-regression. Front Endocrinol (Lausanne). 2022, ' '13:780872. 10.3389/fendo.2022.780872', 'journal-title': 'Front Endocrinol (Lausanne)'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/oby.22859', 'article-title': 'Association of obesity with disease severity among patients with ' 'coronavirus disease 2019', 'volume': '28', 'author': 'Kalligeros M', 'year': '2020', 'unstructured': 'Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, ' 'Mylonakis E. Association of obesity with disease severity among patients ' 'with coronavirus disease 2019. Obesity (Silver Spring). 2020, 28:1200-4. ' '10.1002/oby.22859', 'journal-title': 'Obesity (Silver Spring)'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/CIRCULATIONAHA.120.051936', 'article-title': 'Association of body mass index and age with morbidity and mortality in ' 'patients hospitalized with COVID-19: results from the American Heart ' 'Association COVID-19 Cardiovascular Disease Registry', 'volume': '143', 'author': 'Hendren NS', 'year': '2021', 'unstructured': 'Hendren NS, de Lemos JA, Ayers C, et al.. Association of body mass index ' 'and age with morbidity and mortality in patients hospitalized with ' 'COVID-19: results from the American Heart Association COVID-19 ' 'Cardiovascular Disease Registry. Circulation. 2021, 143:135-44. ' '10.1161/CIRCULATIONAHA.120.051936', 'journal-title': 'Circulation'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41392-020-00454-7', 'article-title': 'Endothelial activation and dysfunction in COVID-19: from basic ' 'mechanisms to potential therapeutic approaches', 'volume': '5', 'author': 'Jin Y', 'year': '2020', 'unstructured': 'Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and ' 'dysfunction in COVID-19: from basic mechanisms to potential therapeutic ' 'approaches. Signal Transduct Target Ther. 2020, 5:293. ' '10.1038/s41392-020-00454-7', 'journal-title': 'Signal Transduct Target Ther'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.3892/mmr.2022.12867', 'article-title': 'Role of endothelial dysfunction in the severity of COVID‑19 infection ' '(review)', 'volume': '26', 'author': 'Kadiyska T', 'year': '2022', 'unstructured': 'Kadiyska T, Tourtourikov I, Dabchev K, et al.. Role of endothelial ' 'dysfunction in the severity of COVID‑19 infection (review). Mol Med Rep. ' '2022, 26:351. 10.3892/mmr.2022.12867', 'journal-title': 'Mol Med Rep'}, { 'key': 'ref7', 'unstructured': 'WHO. Obesity and overweight. (2024). ' 'https.//www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.5114/aoms.2016.58928', 'article-title': 'Obesity and inflammation: the linking mechanism and the complications', 'volume': '13', 'author': 'Ellulu MS', 'year': '2017', 'unstructured': "Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and " 'inflammation: the linking mechanism and the complications. Arch Med Sci. ' '2017, 13:851-63. 10.5114/aoms.2016.58928', 'journal-title': 'Arch Med Sci'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.30269', 'article-title': 'Complete, rapid resolution of severe bilateral pneumonia and acute ' 'respiratory distress syndrome in a COVID-19 patient: role for a unique ' 'therapeutic combination of inhalations with bromhexine, higher doses of ' 'colchicine, and hymecromone', 'volume': '14', 'author': 'Mondeshki T', 'year': '2022', 'unstructured': 'Mondeshki T, Bilyukov R, Tomov T, Mihaylov M, Mitev V. Complete, rapid ' 'resolution of severe bilateral pneumonia and acute respiratory distress ' 'syndrome in a COVID-19 patient: role for a unique therapeutic ' 'combination of inhalations with bromhexine, higher doses of colchicine, ' 'and hymecromone. Cureus. 2022, 14:e30269. 10.7759/cureus.30269', 'journal-title': 'Cureus'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.22541/au.171008530.09561084/v1', 'article-title': 'Effect of increasing doses of colchicine on the treatment of 333 ' 'COVID-19 inpatients. [PREPRINT]', 'author': 'Tiholov R', 'year': '2024', 'unstructured': 'Tiholov R, Lilov A, Georgieva G, Palaveev K, Tashkov K, Mitev V. Effect ' 'of increasing doses of colchicine on the treatment of 333 COVID-19 ' 'inpatients. [PREPRINT]. Authorea. 2024, ' '10.22541/au.171008530.09561084/v1', 'journal-title': 'Authorea'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.35909', 'article-title': 'Effect of an accidental colchicine overdose in a COVID-19 inpatient ' 'with bilateral pneumonia and pericardial effusion', 'volume': '15', 'author': 'Mondeshki T', 'year': '2023', 'unstructured': 'Mondeshki T, Bilyukov R, Mitev V. Effect of an accidental colchicine ' 'overdose in a COVID-19 inpatient with bilateral pneumonia and ' 'pericardial effusion. Cureus. 2023, 15:e35909. 10.7759/cureus.35909', 'journal-title': 'Cureus'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.3897/pharmacia.70.e112550', 'article-title': 'Comparison of treatment of COVID-19 with inhaled bromhexine, higher ' 'doses of colchicine and hymecromone with WHO-recommended Paxlovid, ' 'molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib', 'volume': '70', 'author': 'Mitev V', 'year': '2023', 'unstructured': 'Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, ' 'higher doses of colchicine and hymecromone with WHO-recommended ' 'Paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and ' 'baricitinib. Pharmacia. 2023, 70:1177-93. 10.3897/pharmacia.70.e112550', 'journal-title': 'Pharmacia'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.54441', 'article-title': 'High doses of colchicine act as “silver bullets” against severe ' 'COVID-19', 'volume': '16', 'author': 'Lilov A', 'year': '2024', 'unstructured': 'Lilov A, Palaveev K, Mitev V. High doses of colchicine act as “silver ' 'bullets” against severe COVID-19. Cureus. 2024, 16:e54441. ' '10.7759/cureus.54441', 'journal-title': 'Cureus'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2020.01518', 'article-title': 'Targeting the NLRP3 inflammasome in severe COVID-19', 'volume': '11', 'author': 'Freeman TL', 'year': '2020', 'unstructured': 'Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe ' 'COVID-19. Front Immunol. 2020, 11:1518. 10.3389/fimmu.2020.01518', 'journal-title': 'Front Immunol'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.34221', 'article-title': 'Remdesivir-associated acute liver failure in a COVID-19 patient: a case ' 'report and literature review', 'volume': '15', 'author': 'Ahmed-Khan MA', 'year': '2023', 'unstructured': 'Ahmed-Khan MA, Matar G, Coombes K, Moin K, Joseph BM, Funk CM. ' 'Remdesivir-associated acute liver failure in a COVID-19 patient: a case ' 'report and literature review. Cureus. 2023, 15:e34221. ' '10.7759/cureus.34221', 'journal-title': 'Cureus'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiab247', 'article-title': 'β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis ' 'but is also mutagenic to mammalian cells', 'volume': '224', 'author': 'Zhou S', 'year': '2021', 'unstructured': 'Zhou S, Hill CS, Sarkar S, et al.. β-d-N4-hydroxycytidine inhibits ' 'SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian ' 'cells. J Infect Dis. 2021, 224:415-9. 10.1093/infdis/jiab247', 'journal-title': 'J Infect Dis'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n2663', 'article-title': 'Buyer beware: molnupiravir may damage DNA', 'volume': '375', 'author': 'van Schalkwyk JM', 'year': '2021', 'unstructured': 'van Schalkwyk JM. Buyer beware: molnupiravir may damage DNA. BMJ. 2021, ' '375:n2663. 10.1136/bmj.n2663', 'journal-title': 'BMJ'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v15071451', 'article-title': 'Targeting inflammasome activation in viral infection: a therapeutic ' 'solution?', 'volume': '15', 'author': 'Deng CH', 'year': '2023', 'unstructured': 'Deng CH, Li TQ, Zhang W, Zhao Q, Wang Y. Targeting inflammasome ' 'activation in viral infection: a therapeutic solution?. Viruses. 2023, ' '15:1451. 10.3390/v15071451', 'journal-title': 'Viruses'}, { 'key': 'ref19', 'unstructured': 'How many people die from the flu?. (2022). ' 'https.//ourworldindata.org/influenza-deaths.'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/13102818.2023.2288240', 'article-title': 'What is the lowest lethal dose of colchicine?', 'volume': '37', 'author': 'Mitev V', 'year': '2023', 'unstructured': 'Mitev V. What is the lowest lethal dose of colchicine?. Biotechnol ' 'Biotechnol Equip. 2023, 37:2288240. 10.1080/13102818.2023.2288240', 'journal-title': 'Biotechnol Biotechnol Equip'}], 'container-title': 'Cureus', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.cureus.com/articles/239046-high-dose-colchicine-key-factor-in-the-treatment-of-morbidly-obese-covid-19-patients', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 13]], 'date-time': '2024-04-13T07:51:40Z', 'timestamp': 1712994700000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/239046-high-dose-colchicine-key-factor-in-the-treatment-of-morbidly-obese-covid-19-patients'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 13]]}, 'references-count': 20, 'URL': 'http://dx.doi.org/10.7759/cureus.58164', 'relation': {}, 'ISSN': ['2168-8184'], 'subject': [], 'published': {'date-parts': [[2024, 4, 13]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit